相关实验视频

Updated: Jul 3, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

香的可以通过通过肠道微生物群驱动的托代谢来激活AHR/IL-22/STAT3通路来改善湿热性结肠炎

Yahui Zhang¹, Luoxia Han¹, Jiaqi Dong¹

¹Institute of Traditional Chinese Veterinary Medicine, College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China.

Journal of ethnopharmacology

|February 11, 2024

概括

沙奥 (Shaoyao) (SYD) 通过恢复肠道微生物群和激活AHR/IL-22/STAT3通路,有效治疗湿热性结肠炎. 这种传统中医药增强了肠道屏障功能,减少了炎症,改善了肠道健康.

科学领域:

综合医学是一个整体的医学.
胃肠病学胃肠病学
微生物组研究微生物组研究

背景情况:

香 (Shaoyao Decoction,简称SYD) 是一种传统的中医药,已被证实对湿热性结肠炎的疗效.
在SYD治疗效果的基础上,精确的分子机制在很大程度上仍未被阐明.

研究的目的:

为了研究SYD在湿热结肠炎小鼠模型上的治疗效果.
阐明潜在的机制,包括肠道微生物群调节,托代谢和关键信号通路.

主要方法:

在小鼠中引起的湿热性结肠炎,并用SYD治疗.
对临床和组织病理学结果的评估.
分析炎症标记物,氧化应激,肠道微生物群组成 (16S rRNA测序) 和血清醇衍生物 (代谢学).
检测AHR,CYP1A1,STAT3,紧结蛋白,抗菌和PCNA表达通过西方涂抹,免疫光和免疫组织化学.

主要成果:

SYD治疗缓解了结肠炎症状,减少了结肠炎症,并改善了氧化应激标志物.
SYD调节了肠道微生物群,恢复了托代谢物生产,并激活了AHR/IL-22/STAT3信号通路.
通过增加紧结蛋白表达和促进细胞增殖,SYD增强了肠道屏障功能.

结论:

通过肠道微生物群重组和提升托代谢,SYD可以改善湿热结肠炎.
通过SYD激活AHR/IL-22/STAT3通路有助于恢复肠道粘膜的完整性.
这项研究为SYD治疗大肠炎的治疗作用提供了新的机制性见解.

关键词:

在 AHR/IL-22/STAT3 中.潮湿热性结肠炎的发生我们的肠道微生物群.沙奥 (Shaoyao) 蒸的方法托芬代谢的代谢方式

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...